Zimmer Biomet appoints Dr. Jonathan M. Vigdorchik as Chief Science, Technology and Medical Affairs Officer. PR Newswire Today at 4:30am PDT Experienced orthopedic surgeon from the Hospital for Special Surgery, innovator and former Chief Medical Technology Advisor joins company in an elevated capacity WARSAW, Ind., April 7, 2026 /PRNewswire/ - Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointment of Jonathan M. Vigdorchik, M.D., as Chief Science, Technology and Medical Affairs Officer, effective April 14. In this role, Dr. Vigdorchik will oversee the strategy, delivery, and management of the company's global end-to-end technology portfolio, including AI, robotics, smart implants and data. He will also oversee Zimmer Biomet's Medical Education strategy and Global Advisory Board, helping further strengthen Zimmer Biomet's clinical engagement, innovation roadmap and external scientific leadership. Dr. Vigdorchik will report to Ivan Tornos, Chairman, President and Chief Executive Officer. "Dr. Vigdorchik is a world-class orthopedic surgeon, and he brings exactly the kind of bold, future-focused leadership we need as we continue to shape the next era of musculoskeletal care," said Tornos. "He understands how to translate clinical insight into meaningful innovation, and his leadership will help us move faster, think bigger and continue advancing our broad suite of robotic and enabling technologies. I'm confident he will play a critical role in accelerating our portfolio strategy and further differentiating Zimmer Biomet in the market." Dr. Vigdorchik previously served as Zimmer Biomet's Chief Medical Technology Advisor, Adult Reconstruction and Hip Implants. He is a board-certified, fellowship-trained orthopedic surgeon at Hospital for Special Surgery (HSS) in New York City, specializing in hip and knee replacement surgery. Dr. Vigdorchik held several prominent academic and clinical leadership positions, including serving as Division Chief for national/international reputation and academic promotion on the Adult Reconstruction and Joint Replacement service at HSS and Director of Bone Implant Longevity Research at HSS's Griffin Research Accelerator. In addition, he is currently an Associate Professor of Orthopaedic Surgery at Weill Cornell Medical College. He is active in professional societies including The Hip Society, The Knee Society, the American Academy of Orthopaedic Surgeons (AAOS) and the American Association of Hip and Knee Surgeons (AAHKS), where he served as the Education and Communications Council Chair and earlier served as Program Chair for the 2024 AAHKS Annual Meeting. "As a surgeon and innovator, I believe we are at an inflection point where AI, data, and advanced technology will fundamentally redefine the future of orthopedics," said Dr. Vigdorchik. "I've dedicated my career to focus on preventing complications and achieving consistently better outcomes for patients. With strength across its product portfolio, a differentiated suite of robotic and enabling technologies, and a pathway toward fully autonomous robotic technology in orthopedics, Zimmer Biomet is poised to continue pushing the industry forward. I'm excited to join the talented team in this expanded role to help advance that vision and accelerate innovation for surgeons and patients around the world." Dr. Vigdorchik earned his medical degree from the University of Missouri - Columbia School of Medicine, completed his orthopaedic surgery residency at the Detroit Medical Center / Providence Hospital, and received fellowship training in Adult Reconstruction and Joint Replacement at HSS. He also completed an international traveling fellowship in hip preservation surgery with training at centers in Switzerland, Boston Children's Hospital, and Washington University in St. Louis. About Zimmer Biomet Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation. Cautionary Note Regarding Forward-Looking Statements This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning Zimmer Biomet's expectations, plans, prospects, and product and service offerings, including new product launches and potential clinical successes. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially. For a list and description of some of such risks and uncertainties, see Zimmer Biomet's periodic reports filed with the U.S. Securities and Exchange Commission (SEC). These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Zimmer Biomet's filings with the SEC. Forward-looking statements speak only as of the date they are made, and Zimmer Biomet disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this news release are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this news release. | Contacts: Media Troy Kirkpatrick 614-284-1926 [email protected] Kirsten Fallon 781-779-5561 [email protected] | Investors David DeMartino 646-531-6115 [email protected] Zach Weiner 908-591-6955 [email protected] | SOURCE Zimmer Biomet Holdings, Inc. This is a paid placement. For further inquiries, please contact PR Newswire directly.

Zimmer Biomet wins three awards at Healthcare Asia Medtech Awards 2026. March 27, 2026 Awards Recognize Innovations in Infection Measures, AI-Driven Recovery and Surgeon Engagement across Asia Pacific. SINGAPORE, March 27, 2026 /PRNewswire/ - Zimmer Biomet (NYSE and SIX: ZBH), a global medical technology leader, today announced it received three awards at the Healthcare Asia Medtech Awards 2026, recognizing the company's innovations across orthopedic product development, digital health and surgeon engagement. * Orthopedic Product Innovation Award for its new iodine-treated hip implant; * Digital Innovation of the Year in Australia for its WalkAI knee replacement recovery tracking platform; and * Marketing & Communications Initiative of the Year in Thailand for its You'll Be Back awareness campaign featuring Arnold Schwarzenegger as the company's Chief Movement Officer. "These awards reflect the strength of Zimmer Biomet's innovation and the relevance of our solutions across Asia Pacific," said Sang Yi, Group President, Asia Pacific. "From addressing infection risk with advanced implant technologies, to enabling more proactive, data-driven recoveries and strengthening how we engage surgeons, we are focused on solving the most meaningful health care challenges and improving outcomes for patients across the region." Advancing Infection Measures in Orthopedics Zimmer Biomet received the Orthopedic Product Innovation Award for its implants treated with iodine technology, the iTaperloc Complete and iG7 Hip System. These implants are designed to inhibit bacterial adhesion[1] [,] [2] and reduce the risk of periprosthetic joint infection, a serious complication affecting approximately 1%-2% of primary procedures.[3] Iodine, a biocompatible nutrient, helps prevent biofilm formation without contributing to antibiotic resistance.[4] [,] [5] The technology has received regulatory recognition globally, including approval from Japan's Ministry of Health, Labour and Welfare in September 2025 and Breakthrough Device Designation from the U.S. Food and Drug Administration in October 2025. Advancing Recovery Through AI Zimmer Biomet's WalkAI platform received the Digital Innovation of the Year - Australia award. The application uses artificial intelligence to analyze real-world mobility data and predict a patient's 90-day gait speed following total knee replacement surgery. By identifying deviations in recovery between days 15 and 40 post-surgery, a typically "lower-touch" period in care, WalkAI is designed to flag patients who may not be recovering as expected and enable earlier clinical intervention. This added visibility allows surgeons to prioritize patients who may require closer monitoring or adjustments to rehabilitation, helping reduce the risk of complications. The platform is currently used by more than 180 surgeons across Australia and New Zealand to support over 20,000 knee replacement patients, demonstrating strong clinical adoption and scalability in practice. Raising Awareness of Movement and Treatment Options The Marketing & Communications Initiative of the Year - Thailand award recognized the "You'll Be Back" campaign, which builds on Zimmer Biomet's partnership with Arnold Schwarzenegger as the company's Chief Movement Officer. Launched at the Royal College of Orthopaedic Surgeons of Thailand Annual Conference, the campaign was adapted specifically for a highly regulated market through close collaboration across corporate communications, marketing, legal and compliance teams. Rather than focusing on product promotion, the initiative centered on the importance of movement and aimed to raise awareness of available treatment options for people living with pain. The message resonated strongly by shifting conversations beyond products toward recovery, longevity and quality of life. The campaign significantly increased engagement, with booth interactions tripling year over year and strong resonance among surgeons. The Healthcare Asia Medtech Awards recognize leading companies and innovations across the region, highlighting advancements in medical devices, digital health and patient care solutions. About Zimmer Biomet Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. Siam News Network Pte. Ltd. seamlessly transform the patient experience through its innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Its legacy continues to come to life today through its progressive culture of evolution and innovation. Zimmer Biomet: | Media | Investors | | Addie Elicano | David DeMartino | | 65-8220-8766 | 646-531-6115 | | [email protected] | [email protected] | | Troy Kirkpatrick | Zach Weiner | | 614-284-1926 | 908-591-6955 | | [email protected] | [email protected] | | 1 D. Inoue et al. (2017), Inhibition of biofilm formation on iodine-supported titanium implants, Int Orthop (SICOT) 41: 1093-1099 | | 2 D. Inoue et al. (2019), Iodine-supported titanium implants have good antimicrobial attachment effects, J Orthop Sci 24: 548-551 | | 3 Izakovicova, P., Borens, O., & Trampuz, A. (2019). Periprosthetic joint infection: current concepts and outlook. EFORT open reviews, 4(7), 482-494. https://doi.org/10.1302/2058-5241.4.180092 | | 4 T. Shirai et al. (2013), Antibacterial iodine-supported titanium implants, Acta Biomater 7(4): 1928-1933 | | 5 T. Shirai et al. (2023), Iodine-supported implants in prevention and treatment of surgical site infections for compromised hosts: a prospective study, J Orthop Surg Res 18(1): 388 | The information provided in this article was created by Cision PR Newswire, its news partner. The author's opinions and the content shared on this page are their own and may not necessarily represent the perspectives of Siam News Network.

Zimmer Biomet reported fourth-quarter revenues of $2.24 billion, up 10.9% year on year, exceeding analyst expectations by 0.9%. The orthopaedic products manufacturer, which designs knee and hip replacements and surgical robotics, delivered mixed results with a revenue beat but slightly missed full-year earnings per share guidance. Chief executive Ivan Tornos highlighted the company's strategic progress in 2025, including integrating three acquisitions whilst navigating tariff headwinds. Zimmer Biomet achieved the fastest revenue growth amongst its surgical equipment peers but showed the weakest performance against analyst estimates in the group. The stock remains flat following the earnings announcement and currently trades at $89.99. The surgical equipment sector reported mixed fourth-quarter results overall, with share prices down an average of 11.7% since the latest earnings.